SynthesisPharmaceutical biology2023
Efficacy and safety of
Synthesis in Pharmaceutical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Evaluating hyperbaric oxygen therapy as an adjunct to corticosteroids in sudden sensorineural hearing loss: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Influential publications in sudden hearing loss: a bibliometric and visual synopsis of the top 100 cited articles.Frontiers in neurology · 2024Pooled it
- Efficacy of hyperbaric oxygen therapy in treating sudden sensorineural hearing loss: an umbrella review.Frontiers in neurology · 2024Pooled it
- Low flavonoid intake is associated with bilateral hearing impairment in US older adults.The British journal of nutrition · 2026Article
- Network-Based Identification ofCurrent pharmaceutical design · 2026Article
- Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy.Natural products and bioprospecting · 2025Review
- Combination of Electroacupuncture and Medication for Patients With Tinnitus Associated With Idiopathic Sudden Sensorineural Hearing Loss: Protocol for a Prospective Randomized Controlled Trial.JMIR research protocols · 2025Article
- Studies on the mechanism of ototoxic action of cisplatin and the antagonistic effect of polyphenolic compounds.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
context
objectiveTo evaluate the efficacy and safety of adjuvant GBE in the treatment of SHL. MATERIALS AND
methodsWe used PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, Chinese Scientific Journal Database, China Biomedical Database for literature research, starting from inception to 30 June 2022. The key terms:
resultsOur meta-analysis included 27 articles with a total of 2623 patients. The results revealed that the effects of GBE adjuvant therapy was superior than GT (total effective rate: RR = 1.22, 95% CI: 1.18-1.26,
conclusionThe efficacy of GBE + GT for the treatment of SHL may be more promising than GT alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.